Galera Therapeutics Inc

GRTX

Latest QuantConomy context for GRTX: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.

Asset class

stock

Primary venue

OTC

Recent signals

SEC filings

Asset profile

QuantConomy has a structured record for GRTX. More descriptive asset metadata will appear here when the platform record includes it.

Latest signal rows

Recent signals for GRTX

Scored rows are pulled from the same signal API used by the digests.

Signal	Direction	Score	Observed	Reason
corporate event other event	neutral	70	Jul 7, 12:55 PM	GRTX filed 8-K: Other Events - 1 material event - [strong neutral signal]
fundamental operating income change	bullish	67	May 14, 12:00 AM	GRTX (Q1 2026, operating income): grew 34.9% (-$2.54M → -$1.66M). [sequential period basis, bullish signal]
fundamental eps change	very bearish	64	May 14, 12:00 AM	GRTX (Q1 2026, diluted eps): EPS turned negative ($0.64 → $-0.01). [sequential period basis, very bearish signal]

FUNDAMENTAL signals are experimental: the generator was recently enabled and coverage is still being validated.

Market	Exchange	Source	Asset record
GRTX	OTC	fmp	Galera Therapeutics, Inc.

Buys, last 90d

Sells, last 90d

Rows

Date	Insider	Role	Type	Shares	Price	Value	Filing
May 15, 2026	Emerald Bioventures, LLC	Insider	other	20,813,818	—	—	4 on EDGAR
Apr 7, 2026	CHANG NANCY T	Director, 10% owner	other	1,180,611	—	—	4 on EDGAR
Apr 7, 2026	FRIEDMAN MICHAEL R.	Director	other	5,336,870	—	—	4 on EDGAR
—	Emerald Bioventures, LLC	Insider	—	—	—	—	3 on EDGAR
Nov 20, 2025	Sorensen Mel	President and CEO	sale	70,000	$0.02	$1,407	4 on EDGAR

Source: SEC filings via QuantConomy. Not investment advice.

Get the data

These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.